| Field | Specification |
|---|---|
| Mfr No | |
| Activity | |
| Alternative Names | Acute myeloid leukemia 1 protein (Core-binding factor subunit alpha-2) (CBF-alpha-2) (Oncogene AML-1) (Polyomavirus enhancer-binding protein 2 alpha B subunit) (PEA2-alpha B) (PEBP2-alpha B) (SL3-3 enhancer factor 1 alpha B subunit) (SL3/AKV core-binding factor alpha B subunit) (AML1) (CBFA2) |
| Conjugate | |
| Endotoxin Level | |
| Expression System | |
| Form | Liquid or Lyophilized powder |
| Molecular Weight | |
| Product Type | |
| Protein Length | |
| Purity | |
| Reconstitution | |
| Species | |
| Storage | |
| Target | |
| UniProt # |
Overview
This Recombinant Protein provides recombinant Runx1 from Homo sapiens (Human), produced in E.coli (region 1-453aa). It is commonly used as a defined reagent for assay development, binding studies, and mechanistic research (RUO).
Key elements and design rationale
- Region: 1-453aa (domain boundaries can affect binding/activity readouts).
- Expression host: E.coli (may differ from native PTMs/processing).
- Tag(s): His, Myc (supports purification/detection; consider tag effects in controls).
Biological background
Also reported as Acute myeloid leukemia 1 protein (Core-binding factor subunit alpha-2) (CBF-alpha-2) (Oncogene AML-1) (Polyomavirus enhancer-binding protein 2 alpha B subunit) (PEA2-alpha B) (PEBP2-alpha B) (SL3-3 enhancer factor 1 alpha B subunit) (SL3/AKV core-binding factor alpha B subunit) (AML1) (CBFA2). Forms the heterodimeric complex core-binding factor with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters . Essential for the development of normal hematopoiesis . Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter . Inhibits KAT6B-dependent transcriptional activation . Involved in lineage commitment of immature T cell precursors. CBF complexes repress ZBTB7B transcription factor during cytotoxic T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing . Controls the anergy and suppressive function of regulatory T-cells by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells.
Research relevance and current trends
- Quantitative mapping of ligand/receptor signaling to downstream phospho- and transcriptional programs.
- Use of recombinant standards to improve assay calibration and cross-study comparability.
Forms the heterodimeric complex core-binding factor with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters . Essential for the development of normal hematopoiesis . Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter . Inhibits KAT6B-dependent transcriptional activation . Involved in lineage commitment of immature T cell precursors. CBF complexes repress ZBTB7B transcription factor during cytotoxic T cell development. They bind to RUNX-binding sequence within the ZBTB7B locus acting as transcriptional silencer and allowing for cytotoxic T cell differentiation. CBF complexes binding to the transcriptional silencer is essential for recruitment of nuclear protein complexes that catalyze epigenetic modifications to establish epigenetic ZBTB7B silencing . Controls the anergy and suppressive function of regulatory T-cells by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells
Common research applications
- Standard curve or spike-in reference for quantitative assays involving Runx1
- Binding interaction studies (e.g., SPR/BLI or plate-based binding formats)
- Cell-based stimulation studies with downstream marker readouts (conceptual)
Notes for experimental interpretation
- Recombinant constructs may not capture all native isoforms or PTMs.
- Consider tag- or host-related effects when interpreting binding or activity.
- Use appropriate blanks and matrix/control concepts to separate signal from background.
Can’t Find What You’re Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
